2014-08-07T12:35:54-05:00 2013-12-31 582676261 Rogers & Company PLLC 8300 Boone Boulevard Suite 600 Vienna VA 22182 990 2013-01-01 061389829 Albert B Sabin Vaccine Institute Inc ALBE 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Michael W Marine Chief Executive Officer 2028428610 2014-08-05 1 Nicole M Prince CPA P01315245 7038930300 2014-08-04 2013 2015-11-30 17:44:51Z Michael W Marine 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 27528944 0 X www.sabin.org X 1994 MD An organization of scientists, researchers and advocates for a world free of needless suffering. 10 8 70 0 0 0 25314757 19979693 0 2700 30674 37134 842 0 25346273 20019527 7832968 8369423 0 0 5037610 5297658 52974 27164 284067 8510014 8803203 21433566 22497448 3912707 -2477921 27301935 24430269 2971558 2577813 24330377 21852456 X To reduce needless human suffering from vaccine-preventable and neglected tropical diseases (NTDs) by developing new vaccines, advocating for increased use of existing vaccines, and promoting expanded access to affordable medical treatments. 1 0 6414382 2723484 Sabin Vaccine Insitute Product Development Partnership (Sabin PDP)With 14 years of research and development experience, the Sabin PDP has produced a well-rounded, low-cost model for vaccine development that is a critical component of global efforts to prevent neglected and infectious diseases.Hookworm: The Sabin PDP is currently the only group developing a vaccine for human hookworm disease, an intestinal worm infection that infects more than 700 million people, causing anemia, malnutrition and abdominal pain. The Sabin PDP has two hookworm vaccine candidates currently in development. Both candidates are undergoing Phase 1 clinical testing in either Brazil and/or the United States. The Sabin PDP is also conducting an antigen discovery project to determine if additional or alternative recombinant antigens are viable candidates for a human hookworm vaccine.Schistosomiasis: The Sabin PDP completed manufacture and GLP testing of the vaccine candidate and will soon enter Phase 1 clinical trials. Schistosomiasis is a parasitic disease spread by snails that infects more than 200 million people worldwide; left untreated, the disease can cause fever, organ failure, other chronic diseases and even death. Schistosomiasis is the most deadly parasitic disease after malaria, causing approximately 200,000 deaths annually. Chagas disease: Together with domestic and international academic and industrial partners, the Sabin PDP is developing a new therapeutic vaccine to target Chagas disease, a parasitic disease that can lead to heart failure and affects approximately 10 million people, primarily in Latin America. A therapeutic vaccine is currently in development that would offer a number of improvements over currently available treatments. Leishmaniasis: Since 2011, the Sabin PDP has been working to develop a vaccine to prevent cutaneous leishmaniasis, a parasitic infection transmitted by the bite of a sand fly that causes skin ulcers. The project currently is in the early pre-clinical stage.Severe acute respiratory syndrome (SARS): The Sabin PDP together with partners in the private sector, academia and the military is working to develop and manufacture a vaccine in order to prevent potential SARS outbreaks and improve biodefense preparedness. Pan-anthelminthic Vaccine: In 2013, the Sabin PDP began working to develop a pan-anthelminthic vaccine targeting three major intestinal helminth infections ascariasis, trichuriasis and hookworm infection which cause the highest disease burden of NTDs. 7083360 4210221 Global Network for Neglected Tropical Diseases Program - The Global Network is an advocacy initiative that works in partnership with international agencies, governments, academic institutions, corporations, non-governmental development organizations and the general public to raise the awareness, political will and funding necessary to control and eliminate the seven most common neglected tropical diseases (NTDs) by 2020.The Global Network raises awareness, support and funding for programs that treat and prevent NTD infections, as well as for the integration of NTD programs into existing global health initiatives and international aid budgets.NTDs are a group of 17 parasitic and bacterial infections that impact more than 1 billion people, most of whom live on less than $1.25 per day. The Global Network focuses on the seven most common NTDs lymphatic filariasis, onchocerciasis, schistosomiasis, trachoma, hookworm, trichuriasis and ascariasis. These diseases blind, disable and disfigure their victims, trapping them in a cycle of poverty and disease.But, for approximately 50 cents per year one person can receive treatment and protection against the seven most common NTDs, making NTD control one of the most simple and cost-effective investments in global health and development. Since most of the pills to treat the seven most common NTDs are donated by leading pharmaceutical companies, the costs are limited to distributing medicine to the people who need them most and setting up treatment programs that communities can run themselves. 6928163 1435718 Vaccine Advocacy and Education Programs - The Sabin Vaccine Institute's Vaccine Advocacy and Education program works together with leading health experts and organizations to promote awareness and increased utilization of both existing and new, underutilized vaccines. In 2013, we held various events, including a journalist information session and vaccinology course, to discuss relevant research and updates that informed public health agendas related to rotavirus, meningococcal, typhoid fever, pertussis, rubella and pneumococcal disease. The Sabin Vaccine Institute continued to be responsible for the communications and advocacy needs of the Dengue Vaccine Initiative, a global partnership to increase the priority given to dengue vaccines. The Coalition against Typhoid (CaT) is a global forum of health and immunization experts working to expedite and sustain rational, evidence-based decisions at the global, regional, national and municipal levels regarding the use of typhoid vaccines to prevent childhood enteric fever. CaT also works to define barriers to the adoption of typhoid vaccines in communities that would benefit most and the key activities that are needed to overcome them. The Sabin Vaccine Institute serves as the CaT Secretariat. The CaT objectives are accomplished through the activities of its membership. The Sustainable Immunization Financing (SIF) program operates in twelve African, and six Asian, pilot countries on advocacy-driven initiatives for sustainable immunization financing. SIF invites key stakeholders, parliamentarians, and members of ministries of health and finance to develop innovative financing solutions that sustain vital public health programs. Outputs from such meetings have ranged from declarations and ideas for tax-devoted funding to conceiving financing mechanisms, all in support of this initiative. In June 2013, Sabin launched the International Association of Immunization Managers (IAIM). This is the first-ever international association of this type. Through its membership, IAIM's goal is to help drive the achievement of national, regional and international immunization goals, including those in the Global Vaccine Action Plan (GVAP), by fostering forward-thinking and superior management of immunization programs. 20425905 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 1 0 0 0 1 1 0 1 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 28 0 1 70 1 0 0 0 0 0 0 0 0 0 0 X 10 8 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 MD DC NY CA FL X The Organization 2028428610 2000 Pennsylvania Avenue NW No 7100 Washington DC 20006 Morton Hyman Chairman 20.00 X X 0 0 0 Mike Whitham Treasurer 1.00 X X 0 0 0 Baroness Helene Hayman Officer 1.00 X 0 0 0 Axel Hoos Trustee 1.00 X 0 0 0 Paul Maddon Trustee 1.00 X 0 0 0 Michael Posner Trustee 1.00 X 0 0 0 Gary Rosenthal Trustee 1.00 X 0 0 0 Philip Russell Trustee 5.00 X 9200 0 0 Marc Shapiro Trustee 1.00 X 0 0 0 Peter Thoren Trustee 1.00 X 0 0 0 Brian Davis Chief Operating Officer 40.00 X 210088 0 21635 Peter Hotez President, Ex Officio Trus 10.00 X 75000 0 0 Ciro de Quadros Exec VP, Ex Officio Truste 40.00 X 344900 0 1256 Michael Marine CEO, Ex Officio Trustee 40.00 X 284834 0 11423 Neeraj Mistry Program Director 40.00 X 231666 0 14079 Larry Ellingswoth Program Director 40.00 X 209854 0 6261 Michael McQuestion Program Director 40.00 X 195602 0 21871 Christopher Nelson Program Director 40.00 X 192685 0 21534 Ana Flavia Caravalho Program Director 40.00 X 138082 0 5360 1891911 0 103419 14 0 1 0 MOST Investments LLC 2500 Wilson Blvd Ste 200 Arlington VA 22201 Web development, hosting and maintenance 158719 Fraunhofer USA Inc POBox 673308 Detroit MI 48267 Vaccine testing and process improvements 132803 Creative Collaborations 50B Pember Road London England UK NW10 5LU Advocacy Campaign Manager 125142 JAK Foundation 9 Sixth Circular Road PO Box CT 51 Accra Ghana GH Envoy Program for Global Network 115000 DF Net Research Inc 140 Lakeside Avenue Seattle WA 98122 Clinical trial data management 100063 5 2214252 17765441 4829 19979693 Membership dues 900099 2700 2700 2700 24246 24246 7522305 7509417 12888 12888 12888 20019527 2700 0 37134 X 4380742 4380742 3988681 3988681 958353 761104 162279 34970 3606664 2857140 616641 132883 101753 80607 17397 3749 333930 272037 50471 11422 296958 237905 47632 11421 38882 34361 3495 1026 17186 15187 1545 454 27164 27164 4213841 4127813 66848 19180 433094 404196 27716 1182 270192 218128 48974 3090 11872 3956 7916 539933 35924 504009 825743 809155 5256 11332 2139536 2102910 36519 107 1871 1430 441 17760 17760 117704 42770 74934 Bad debt 71058 71058 Dues/subscriptions 39824 25644 8707 5473 Recruitment 28511 22898 3612 2001 Books/publications 6199 3554 1000 1645 29997 -237 13266 16968 22497448 20425905 1787476 284067 24567247 20144024 2413487 3948788 35893 70546 178909 164777 309731 241672 72324 68059 34075 34075 27301935 24430269 2503493 2191587 260964 204589 207101 181637 2971558 2577813 X 2138685 2303747 22191692 19548709 24330377 21852456 27301935 24430269 -2477921 0 X X 0 1 X 1 0 X 17123901 21076480 21900847 25314757 19979693 105395678 17123901 21076480 21900847 25314757 19979693 105395678 69479006 35916672 92623 25207 24717 30674 24246 197467 105593145 7700 0.34010 0.27080 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 719 1411 2130 22495318 22497448 1000000 250000 0 0 1000000 1000000 1500000 2130 2130 250000 250000 375000 719 719 309731 241672 68059 68059 Obligation under capital lease 3391 Deferred rent 178246 181637 X 20110543 91016 91016 20019527 0 20019527 22588464 91016 91016 22497448 0 22497448 Part X, Line 2: Management evaluated the Institute's tax positions and concluded that the Institute's financial statements do not include any uncertain tax positions. 1 Europe (Including Iceland & Greenland) - 0 0 Grants to recipients located in region NTD Control, Typhoid Vaccine Management, General Support 2881849 South America - Argentina, Bolivia, 0 0 Grants to recipients located in region Vaccine Development 732979 East Asia and the Pacific - 0 0 Grants to recipients located in region NTD Control, Vaccine Development 372289 Middle East and North Africa 0 0 Grants to recipients located in region NTD Control 1564 0 0 0 0 0 0 3988681 0 3988681 Europe (Including Iceland & Greenland) - NTD Control 2300000 EFT Europe (Including Iceland & Greenland) - Typhoid Vaccine Management 376403 EFT Europe (Including Iceland & Greenland) - Typhoid Vaccine Management 148482 EFT South America Vaccine Development 732979 EFT East Asia & Pacific NTD Control 193228 EFT East Asia & Pacific Vaccine Development 179061 EFT Europe (Including Iceland & Greenland) - Albania, Andorra, Austria, Belgium General Support 56964 EFT 4 1 0 0 0 0 0 0 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X X X X X 1 The Social Investment Consultancy 338 City Road London UK EC1V 2PY Development strategy and outreach 0 1041 27164 26123 1041 27164 26123 DC MD NY CA FL 1 The World Bank 1818 H Street NW Washington DC 20433 1500000 NTD Control Pan American Health Organization 525 23rd Street NW Washington DC 20037 130634 NTD Control Pan American Health Organization 525 23rd Street NW Washington DC 20037 910833 Vaccine Advocacy Baylor College of Medicine 1 Baylor Plaza Houston TX 77030 741613878 861167 Vaccine Development The George Washington University 2300 I Street NW Washington DC 20147 530196584 818560 Vaccine Development The University of Kansas Center for Research 2385 Irving Hill Road Lawrence KS 66045 480680117 131718 Vaccine Development Helen Keller International 352 Park Avenue South 12th Floor New York NY 10010 135562162 27830 NTD Control 0 7 Part I, Line 2: Grants are monitored in several ways. First, there is a due diligence process in awarding the grant. Second, a written and signed agreement is executed, which includes a detailed scope of work, budget and reporting requirements. Typically, payments are sent either when milestones are met or in accordance with an established payment schedule. Third, we require monthly, quarterly, and/or annual financial and technical reports from recipients prior to sending the subsequent payment. Fourth, and as needed, we conduct site visits. And finally, if deemed necessary, a third party reviews the accounting records of the recipient(s). X X X 0 0 0 0 0 0 0 0 0 Brian Davis Chief Operating Officer 195088 0 15000 0 0 0 8000 0 13635 0 231723 0 0 0 Ciro de Quadros Exec VP, Ex Officio Truste 299900 0 45000 0 0 0 0 0 1256 0 346156 0 0 0 Michael Marine CEO, Ex Officio Trustee 249834 0 35000 0 0 0 10000 0 1423 0 296257 0 0 0 Neeraj Mistry Program Director 221666 0 10000 0 0 0 0 0 14079 0 245745 0 0 0 Larry Ellingswoth Program Director 209854 0 0 0 0 0 0 0 6261 0 216115 0 0 0 Michael McQuestion Program Director 195602 0 0 0 0 0 7904 0 13967 0 217473 0 0 0 Christopher Nelson Program Director 192685 0 0 0 0 0 7904 0 13630 0 214219 0 0 0 Form 990, Part III, line 2 The International Association of Immunization Managers (IAIM) launched in 2013. The IAIM is part of Sabin's Vaccine Advocacy and Education program. Through interation with its membership, IAIM's goal is to help drive the achievement of national, regional and international immunization goals, including those in the Global Vaccine Action Plan (GVAP), by fostering forward-thinking and superior management of immunization programs. Form 990, Part VI, Section B, line 11 The Form 990 is prepared by an outside tax accountant. It is first reviewed by the COO and then presented to the CEO and Finance Committee for their review and approval. Finally it is presented to the full Board of Trustees for their review before filing. Form 990, Part VI, Section B, line 12c Sabin's management and Board Chair are reponsible for ensuring the conflict of interest policy is up-to-date and adhered to by the Trustees. Form 990, Part VI, Section B, line 15 Compensation of officers and/or key employees is set in consultation with input from the Board or Chair as appropriate. Sabin uses a mix of data points including: independent salary surveys; comparable pay by similar organizations; compensation firms and our own internal pay scale. Form 990, Part VI, Section C, line 19 Governing documents (upon request), conflict of interest policy (upon request), and financial statement (Sabin's website). Form 990, Part IX, line 11g Vaccine development program contract expenses: Program service expenses 2,123,122. Management and general expenses 0. Fundraising expenses 0. Total expenses 2,123,122. Transcription Service: Program service expenses 16,529. Management and general expenses 1,681. Fundraising expenses 494. Total expenses 18,704. Consulting: Program service expenses 1,988,162. Management and general expenses 65,167. Fundraising expenses 18,686. Total expenses 2,072,015. Form 990, Part XII, Line 2c: The Organization has a finance committee that assumes responsibility for oversight of the audit. This process is consistent with prior years.